Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.29) earnings per share for the quarter, FiscalAI reports. Atara Biotherapeutics had a negative return on equity of 79.12% and a net margin of 27.07%.The company had revenue of $0.52 million for the quarter.

Atara Biotherapeutics Stock Performance

NASDAQ ATRA traded up $1.03 during trading hours on Tuesday, reaching $9.81. The company’s stock had a trading volume of 1,044,411 shares, compared to its average volume of 1,234,964. The stock has a market cap of $83.48 million, a PE ratio of 3.14 and a beta of -0.30. Atara Biotherapeutics has a fifty-two week low of $3.92 and a fifty-two week high of $19.15. The company’s 50-day moving average is $5.39 and its two-hundred day moving average is $9.21.

Key Stories Impacting Atara Biotherapeutics

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Atara reported a stronger-than-expected quarterly loss earlier in March, with EPS of ($0.25) versus analyst expectations of ($0.68), and revenue of $1.60 million versus estimates of $0.70 million. That beat may still be supporting investor sentiment around the stock. Atara Biotherapeutics stock page
• Neutral Sentiment: Multiple law firms issued reminders about the May 22, 2026 lead plaintiff deadline in an existing securities class action tied to ATRA purchases made between May 20, 2024 and January 9, 2026. These notices mainly keep the lawsuit in focus rather than change the underlying case. Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
• Neutral Sentiment: Atara’s major shareholder Innovation Ltd Panacea disclosed a sale of 313,446 shares at an average price of $10.10, trimming its stake by 23.67%. Insider selling can add caution, but the market may view it as routine disclosure rather than a direct business warning. Atara Biotherapeutics (NASDAQ:ATRA) Major Shareholder Sells $3,165,804.60 in Stock
• Negative Sentiment: The ongoing securities class action and repeated law-firm solicitations may weigh on sentiment by highlighting legal overhang and potential uncertainty for shareholders. Atara Biotherapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA

Insider Transactions at Atara Biotherapeutics

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea sold 313,446 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $10.10, for a total value of $3,165,804.60. Following the sale, the insider owned 1,011,000 shares of the company’s stock, valued at $10,211,100. This represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 41.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new position in Atara Biotherapeutics in the 2nd quarter valued at $31,000. Dimensional Fund Advisors LP acquired a new stake in shares of Atara Biotherapeutics during the fourth quarter worth $181,000. Walleye Capital LLC purchased a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at $220,000. Marshall Wace LLP purchased a new stake in shares of Atara Biotherapeutics in the second quarter valued at $327,000. Finally, Quadrature Capital Ltd increased its stake in Atara Biotherapeutics by 22.8% in the fourth quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 3,779 shares during the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wall Street Zen cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Canaccord Genuity Group set a $13.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research report on Friday. New Street Research set a $6.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, January 13th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Atara Biotherapeutics in a research report on Friday, March 27th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $9.50.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.